FibroGen (NASDAQ:FGEN) Receives “Market Perform” Rating from William Blair

William Blair reaffirmed their market perform rating on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Wednesday morning,RTT News reports.

Separately, StockNews.com began coverage on shares of FibroGen in a research note on Wednesday, November 6th. They issued a “hold” rating for the company.

FibroGen Trading Down 0.6 %

Shares of FibroGen stock traded down $0.00 on Wednesday, hitting $0.33. 182,782 shares of the company traded hands, compared to its average volume of 2,222,746. The company has a market cap of $33.15 million, a PE ratio of -0.27 and a beta of 0.72. The stock’s 50 day moving average price is $0.37 and its 200-day moving average price is $0.72. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period last year, the firm earned ($0.52) earnings per share. As a group, research analysts anticipate that FibroGen will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Several institutional investors have recently bought and sold shares of FGEN. Cubist Systematic Strategies LLC boosted its position in FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 280,161 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in FibroGen in the first quarter valued at about $131,000. Acadian Asset Management LLC raised its holdings in FibroGen by 1.4% in the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after purchasing an additional 34,937 shares in the last quarter. Point72 DIFC Ltd raised its holdings in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of FibroGen in the 2nd quarter valued at about $424,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.